153 related articles for article (PubMed ID: 16734730)
21. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts.
Ishikawa T; Utoh M; Sawada N; Nishida M; Fukase Y; Sekiguchi F; Ishitsuka H
Biochem Pharmacol; 1998 Apr; 55(7):1091-7. PubMed ID: 9605432
[TBL] [Abstract][Full Text] [Related]
22. Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.
Koda K; Miyauchi H; Kosugi C; Kaiho T; Takiguchi N; Kobayashi S; Maruyama T; Matsubara H;
Anticancer Res; 2016 Oct; 36(10):5325-5331. PubMed ID: 27798895
[TBL] [Abstract][Full Text] [Related]
23. Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism.
Sasaki E; Tominaga K; Kuwamura H; Watanabe T; Fujiwara Y; Oshitani N; Higuchi K; Arakawa T
J Gastroenterol; 2007 Oct; 42(10):816-22. PubMed ID: 17940834
[TBL] [Abstract][Full Text] [Related]
24. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs.
Zembutsu H; Ohnishi Y; Tsunoda T; Furukawa Y; Katagiri T; Ueyama Y; Tamaoki N; Nomura T; Kitahara O; Yanagawa R; Hirata K; Nakamura Y
Cancer Res; 2002 Jan; 62(2):518-27. PubMed ID: 11809704
[TBL] [Abstract][Full Text] [Related]
25. Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase.
Réti A; Pap E; Adleff V; Jeney A; Kralovánszky J; Budai B
Cancer Chemother Pharmacol; 2010 Jul; 66(2):219-27. PubMed ID: 19830428
[TBL] [Abstract][Full Text] [Related]
26. The role of additional chemotherapy with oral UFT in intravenous combination chemotherapy with cisplatin and 5-fluorouracil for human gastric cancer xenograft lines of well- and poorly- differentiated adenocarcinomas transplanted in nude mice.
Tseng CC; Nio Y; Tsubono M; Kawabata K; Masai Y; Hayashi H; Fukumoto M; Tobe T
Anticancer Res; 1992; 12(4):1295-9. PubMed ID: 1503424
[TBL] [Abstract][Full Text] [Related]
27. [Relationship between the anti-metastatic effect of UFT and in vitro chemosensitivity to 5-FU in metastatic tumors from orthotopic implanted colon cancer in nude rats].
Ogata Y; Akagi Y; Nozoe Y; Sasatomi T; Miyagi Y; Nakagawa M; Matono K; Kobayashi H; Shirouzu K
Gan To Kagaku Ryoho; 2001 May; 28(5):655-60. PubMed ID: 11383214
[TBL] [Abstract][Full Text] [Related]
28. Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts.
Fukushima M; Satake H; Uchida J; Shimamoto Y; Kato T; Takechi T; Okabe H; Fujioka A; Nakano K; Ohshimo H; Takeda S; Shirasaka T
Int J Oncol; 1998 Oct; 13(4):693-8. PubMed ID: 9735397
[TBL] [Abstract][Full Text] [Related]
29. Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts.
de la Cueva A; Ramírez de Molina A; Alvarez-Ayerza N; Ramos MA; Cebrián A; Del Pulgar TG; Lacal JC
PLoS One; 2013; 8(6):e64961. PubMed ID: 23762272
[TBL] [Abstract][Full Text] [Related]
30. Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine (capecitabine).
Ishikawa T; Fukase Y; Yamamoto T; Sekiguchi F; Ishitsuka H
Biol Pharm Bull; 1998 Jul; 21(7):713-7. PubMed ID: 9703255
[TBL] [Abstract][Full Text] [Related]
31. Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in breast cancer predicts 5-FU sensitivity by a histocultural drug sensitivity test.
Kakimoto M; Uetake H; Osanai T; Shirota Y; Takagi Y; Takeshita E; Toriya Y; Danenberg K; Danenberg PV; Sugihara K
Cancer Lett; 2005 Jun; 223(1):103-11. PubMed ID: 15890242
[TBL] [Abstract][Full Text] [Related]
32. Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.
Nukatsuka M; Saito H; Nakagawa F; Abe M; Uchida J; Shibata J; Matsuo K; Noguchi S; Kiniwa M
Breast Cancer Res Treat; 2011 Jul; 128(2):381-90. PubMed ID: 20809360
[TBL] [Abstract][Full Text] [Related]
33. The transfection of thymidylate synthase antisense suppresses oncogenic properties of a human colon cancer cell line and augments the antitumor effect of fluorouracil.
Matsuoka K; Tsukuda K; Suda M; Kobayashi K; Ota T; Okita A; Watanabe K; Suzuki E; Murakami M; Doihara H; Shimizu N
Int J Oncol; 2004 Jan; 24(1):217-22. PubMed ID: 14654960
[TBL] [Abstract][Full Text] [Related]
34. Clinical implications of dihydropyrimidine dehydrogenase inhibition.
Diasio RB
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):17-21. PubMed ID: 10442353
[TBL] [Abstract][Full Text] [Related]
35. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
Omura K
Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
[TBL] [Abstract][Full Text] [Related]
36. Dependence of chemotherapy response on p53 mutation status in a panel of human cancer lines maintained in nude mice.
Koike M; Fujita F; Komori K; Katoh F; Sugimoto T; Sakamoto Y; Matsuda M; Fujita M
Cancer Sci; 2004 Jun; 95(6):541-6. PubMed ID: 15182437
[TBL] [Abstract][Full Text] [Related]
37. Gene expression profile of 5-fluorouracil metabolic enzymes in primary colorectal cancer: potential as predictive parameters for response to fluorouracil-based chemotherapy.
Kinoshita M; Kodera Y; Hibi K; Nakayama G; Inoue T; Ohashi N; Ito Y; Koike M; Fujiwara M; Nakao A
Anticancer Res; 2007; 27(2):851-6. PubMed ID: 17465211
[TBL] [Abstract][Full Text] [Related]
38. Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation.
Milano G; Ferrero JM; François E
Br J Cancer; 2004 Aug; 91(4):613-7. PubMed ID: 15280932
[TBL] [Abstract][Full Text] [Related]
39. Carcinoembryonic antigen expression level as a predictive factor for response to 5-fluorouracil in colorectal cancer.
Eftekhar E; Naghibalhossaini F
Mol Biol Rep; 2014 Jan; 41(1):459-66. PubMed ID: 24293105
[TBL] [Abstract][Full Text] [Related]
40. Anti-metastatic effect of capecitabine on human colon cancer xenografts in nude mouse rectum.
Ninomiya I; Terada I; Yoshizumi T; Takino T; Nagai N; Morita A; Fushida S; Nishimura G; Fujimura T; Ohta T; Miwa K
Int J Cancer; 2004 Oct; 112(1):135-42. PubMed ID: 15305385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
